Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rensheng Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Li Jiang

    Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China

    2 shared publications
  • Shanshan Ma

    Department of Radiation Therapy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

    2 shared publications
  • Tingting Zhang

    Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China

    2 shared publications
  • Bo Li

    Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China

    1 shared publication
  • Chang Liu

    Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

    1 shared publication
  • Keyu Lu

    Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Sonophoresis Enhanced Transdermal Delivery of Cisplatin in the Xenografted Tumor Model of Cervical Cancer

    by Shanshan Ma, Chang Liu, Bo Li, Tingting Zhang, Li Jiang, Rensheng Wang

    Background: Transdermal drug delivery system has been researched for a long time because of its advantage in decreasing side effects such as nausea, vomiting, and gastrointestinal disturbance. Sonophoresis has been shown to be very effective in promoting the transdermal delivery of drugs. This study is on purpose to research the feasibility of sonophoresis promoting cisplatin in the treatment of cervical cancer and the optimum drug delivery mode. Methods: Thirty-two female nude-mice model of cervical cancer were randomly divided into 4 groups (n=8 in each group): control group without any intervention, low, medium and high concentration groups were treated with the corresponding cisplatin concentrations of 0.2mg/mL, 0.4mg/mL and 0.8mg/mL, respectively, with concurrent sonophoresis applied on the skin of local tumor, 1 mL at a time, once a day for a total of 5 days. Therapeutic pulsed ultrasound (TPU) was 1.0 MHz, 2.0 W/cm2 and 60-min duration. Weight of mice and tumor diameters were measured every day during the intervention. The concentration of cisplatin in tumors was detected by HPLC. Meanwhile, tumor, skin, liver and kidney gross structures and ultrastructure were observed in order to evaluate the effectiveness and safety of experimental conditions. In addition, apoptosis and proliferation-related factors (MPO, Caspase-3, PCNA) were detected by immunohistochemistry, immunofluorescence and TUNEL assay. Results: The weight of nude mice in each group showed an increasing trend, except for a decrease of weight in the 0.8 mg/mL group. No obvious tumor inhibition effect was observed. Cisplatin was detected in the 0.4 mg/mL group and 0.8 mg/mL group, with relative concentrations of 0.081± 0.033 mg/mL and 0.111± 0.021 mg/mL, respectively. Both skin and kidney inflammation were observed in the 0.8 mg/mL group. The expression of MPO, caspase-3 and TUNEL was concentration dependent, with the highest expression in the 0.8 mg/mL group, followed by the 0.4 mg/mL group, with no significant differences between the control and the 0.2 mg/mL group. PCNA was highly expressed in both the control and 0.2 mg/mL groups but decreased in the 0.4 mg/mL and 0.8 mg/mL groups. Conclusion: Sonophoresis enhanced transdermal delivery of cisplatin in a xenograft tumor model of cervical cancer. Considering the occurrence of skin inflammation and renal injury caused by cisplatin, the recommended concentration to be administered is 0.4mg/mL.


  • Open Access

    Impact of bladder volume on treatment planning and clinical outcomes of radiotherapy for patients with cervical cancer

    by Shanshan Ma, Tingting Zhang, Li Jiang, Wen Qin, Keyu Lu, Yong Zhang, Rensheng Wang

    Objective: This study aimed to investigate the impact of bladder volume on treatment planning and clinical outcomes of radiotherapy for patients with cervical cancer. Materials and methods: One hundred and sixty-six patients with locally advanced cervical cancer were selected in this retrospective study. The patients were divided into four groups according to their average bladder volume during radiotherapy (external beam radiation therapy and intracavitary brachytherapy): group A: VResults: The median follow-up time was 28 months. The D90 and D2cc of the rectum in group A were the highest (PPPP=0.022, respectively), with group A the most serious and group B the mildest. Conclusion: For patients with cervical cancer, the bladder volume significantly affected the delivered dose to target, rectum, and bladder. When the bladder volume range was 100–150 mL, the rate of late radiation-induced proctitis and cystitis was low and the degree of reaction was mild. This is thought to be the optimum bladder volume for patients with cervical cancer during radiotherapy.